{"cord_uid": "0kds2pz3", "sha": "46dc2d1f518d1235d8ad72096665139352edf72e", "source_x": "Elsevier; Medline; PMC", "title": "Remdesivir for COVID-19: challenges of underpowered studies", "doi": "10.1016/s0140-6736(20)31023-0", "pmcid": "PMC7190306", "pubmed_id": "32423580", "license": "els-covid", "abstract": "", "publish_time": "2020-04-29", "authors": "Norrie, John David", "journal": "Lancet", "mag_id": "", "who_covidence_id": "", "arxiv_id": "", "pdf_json_files": ["document_parses/pdf_json/46dc2d1f518d1235d8ad72096665139352edf72e.json"], "pmc_json_files": ["document_parses/pmc_json/PMC7190306.xml.json"], "url": "https://doi.org/10.1016/s0140-6736(20)31023-0; https://www.ncbi.nlm.nih.gov/pubmed/32423580/; https://api.elsevier.com/content/article/pii/S0140673620310230; https://www.sciencedirect.com/science/article/pii/S0140673620310230", "s2_id": "216642405"}